| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5654301 | UCB INC | Amino acid derivative anticonvulsant |
Aug, 2014
(9 years ago) | |
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(2 years ago) | |
Vimpat is owned by Ucb Inc.
Vimpat contains Lacosamide.
Vimpat has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vimpat are:
- US5654301
- USRE38551
Vimpat was authorised for market use on 28 October, 2008.
Vimpat is available in solution;oral, solution;intravenous, tablet;oral dosage forms.
Vimpat can be used as method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older, method of treating, as monotherapy or adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older when oral administration is temporarily not feasible.
Drug patent challenges can be filed against Vimpat from 28 October, 2012.
The generics of Vimpat are possible to be released after 28 April, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-188) | Apr 28, 2026 |
| New Patient Population(NPP) | Oct 14, 2024 |
| New Dosing Schedule(D-144) | Aug 29, 2017 |
| New Indication(I-696) | Aug 29, 2017 |
| New Dosing Schedule(D-143) | Aug 29, 2017 |
| New Indication(I-878) | Nov 16, 2023 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2013 |
Drugs and Companies using LACOSAMIDE ingredient
NCE-1 date: 28 October, 2012
Market Authorisation Date: 28 October, 2008
Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older; Method of treating, as monotherapy or adjunctive therapy, partial-onset seizures i...
Dosage: TABLET;ORAL; SOLUTION;ORAL; SOLUTION;INTRAVENOUS
VIMPAT family patents
